Antiangiogenic Properties of Fibstatin, an Extracellular FGF-2–Binding Polypeptide

By using the two-hybrid system with basic fibroblast growth factor (FGF-2) as bait, we isolated and characterized fibstatin, an endogenous Mr 29,000 human basement membrane-derived inhibitor of angiogenesis and tumor growth. Fibstatin, a fragment containing the type III domains 12–14 of fibronectin, was produced as a recombinant protein and was shown to inhibit the proliferation, migration, and differentiation of endothelial cells in vitro. Antiangiogenic activity of fibstatin was confirmed in a Matrigel angiogenesis assay in vivo, and electrotransfer of the fibstatin gene into muscle tissue resulted in reduced B16F10 tumor growth. Taken together, these results suggest that fibstatin could act as a powerful molecule for antiangiogenic therapy.

[1]  Raghu Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Humphries,et al.  Identification of a novel recognition sequence for the integrin alpha 4 beta 1 in the COOH‐terminal heparin‐binding domain of fibronectin. , 1991, The EMBO journal.

[3]  D. Rifkin,et al.  Biological roles of fibroblast growth factor-2. , 1997, Endocrine reviews.

[4]  J. Williams,et al.  Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. , 1985, The American journal of pathology.

[5]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[6]  L. Créancier,et al.  New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. , 2001, Molecular endocrinology.

[7]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Mohri,et al.  Binding site in human plasma fibronectin to HL-60 cells localizes in the C-terminal heparin-binding region independently of RGD and CS1. , 1995, Experimental cell research.

[9]  A. Mir,et al.  Expression of a membrane-bound form of Trypanosoma cruzi trans-sialidase in baculovirus-infected insect cells: a potential tool for sialylation of glycoproteins produced in the baculovirus-insect cells system. , 2001, Glycobiology.

[10]  J. Shiloach,et al.  Zinc-binding of endostatin is essential for its antiangiogenic activity. , 1998, Biochemical and biophysical research communications.

[11]  R. Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Harris,et al.  Single-Step Purification / Solubilization of Recombinant Proteins : Application to Surfactant Protein B , 1999 .

[13]  A. Prats,et al.  cis-acting elements involved in the alternative translation initiation process of human basic fibroblast growth factor mRNA , 1992, Molecular and cellular biology.

[14]  A. Bikfalvi,et al.  Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. , 1998, Blood.

[15]  Amit Kumar Sharma,et al.  Crystal structure of a heparin‐ and integrin‐binding segment of human fibronectin , 1999, The EMBO journal.

[16]  S. P. Levine,et al.  Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4. , 1976, The Journal of biological chemistry.

[17]  G. Taraboletti,et al.  The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  H. Prats,et al.  Translokin is an intracellular mediator of FGF-2 trafficking , 2003, Nature Cell Biology.

[19]  A. Stewart,et al.  Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. , 2001, Human gene therapy.

[20]  C. Giraud,et al.  Competition between baculovirus polyhedrin and p10 gene expression during infection of insect cells , 1993, Journal of virology.

[21]  M. Summers,et al.  A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures. , 1987 .

[22]  E. Flemington,et al.  Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1 , 1995, Journal of virology.

[23]  H Laurell,et al.  FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2. , 2000, Molecular endocrinology.

[24]  Lee Chao,et al.  Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.

[25]  V. Baldin,et al.  Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. , 1990, The EMBO journal.

[26]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[27]  I. Campbell,et al.  Mapping the Heparin-binding Site on the13–14F3 Fragment of Fibronectin* , 2002, The Journal of Biological Chemistry.

[28]  H. Mohri,et al.  Identification of a Novel Binding Site to the Integrin αIIbβ3 Located in the C-terminal Heparin-binding Domain of Human Plasma Fibronectin* , 1996, The Journal of Biological Chemistry.